Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

Autoinjector preference among patients with multiple sclerosis: results from a national survey.

Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I, Schreiner T.

Patient Prefer Adherence. 2017 Aug 3;11:1325-1334. doi: 10.2147/PPA.S137741. eCollection 2017.

2.

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7.

3.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

4.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

5.

Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).

Meissner A, Limmroth V.

Mult Scler Relat Disord. 2016 Jul;8:19-26. doi: 10.1016/j.msard.2016.04.002. Epub 2016 Apr 21. Review.

PMID:
27456870
6.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.

BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0.

7.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

8.

Comment: Monoclonal antibodies in chronic migraine-Are early effects meaningful?

Limmroth V.

Neurology. 2016 Jul 5;87(1):47. doi: 10.1212/WNL.0000000000002819. Epub 2016 Jun 8. No abstract available.

PMID:
27281535
9.

[Could salt trigger autoimmune diseases?].

Limmroth V.

MMW Fortschr Med. 2016 May 12;158(9):38. doi: 10.1007/s15006-016-8203-3. German. No abstract available.

PMID:
27155703
10.

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.

Zettl UK, Bauer-Steinhusen U, Glaser T, Czekalla J, Hechenbichler K, Limmroth V, Hecker M.

Adv Ther. 2016 May;33(5):834-47. doi: 10.1007/s12325-016-0325-6. Epub 2016 Apr 18.

PMID:
27090116
11.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
12.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

13.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
14.

Case Report: Human Bocavirus Associated Pneumonia as Cause of Acute Injury, Cologne, Germany.

Krakau M, Gerbershagen K, Frost U, Hinzke M, Brockmann M, Schildgen V, Gomann A, Limmroth V, Dormann A, Schildgen O.

Medicine (Baltimore). 2015 Oct;94(42):e1587. doi: 10.1097/MD.0000000000001587.

15.

Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program.

Katsarava Z, Ehlken B, Limmroth V, Taipale K, Patel SN, Niemczyk G, Rehberg-Weber K, Wernsdörfer C; C.A.R.E. Study Group.

BMC Neurol. 2015 Sep 22;15:170. doi: 10.1186/s12883-015-0426-x.

16.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
17.

A systematic review of aspirin in primary prevention: is it time for a new approach?

Brotons C, Benamouzig R, Filipiak KJ, Limmroth V, Borghi C.

Am J Cardiovasc Drugs. 2015 Apr;15(2):113-33. doi: 10.1007/s40256-014-0100-5. Review.

18.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2015 Jul;21(8):1036-44. doi: 10.1177/1352458514556296. Epub 2014 Nov 12.

PMID:
25392339
19.

[Juvenile multiple sclerosis is increasing].

Limmroth V.

MMW Fortschr Med. 2014 Jun 26;156(12):26. German. No abstract available.

PMID:
25369676
20.

Treatment of relapsing-remitting multiple sclerosis: current and future algorithms.

Limmroth V.

Eur Neurol. 2014;72 Suppl 1:35-8. doi: 10.1159/000367624. Epub 2014 Sep 26. No abstract available.

Supplemental Content

Loading ...
Support Center